Request Discount

Ulcerative Colitis Market (Drug Type - Anti-inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, and Other Drug Types; Disease Type - Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025

  • Published : September, 2019

  • Rep Id : HC0666

  • Category : Healthcare & Medical Devices

  • Status : Published

This report provides exclusive insights into the COVID-19 impact on the Ulcerative Colitis Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Ulcerative Colitis Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Ulcerative Colitis Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.

A recent report published by Infinium Global Research on ulcerative colitis market provides an in-depth analysis of segments and sub-segments in the global as well as regional ulcerative colitis market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional ulcerative colitis market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global ulcerative colitis market. According to the report, the global ulcerative colitis market is projected to grow at a healthy CAGR over the forecast period of 2019-2025.


Market Insight

According to the CDC (Centers for Disease Control), the worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000 persons per year. The recurrence of the disease’s symptoms is also high. Recently, numerous medical treatments for ulcerative colitis have developed. 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) treatments are recent medical treatments. Furthermore, golimumab, vedolizumab, AJM300, tofacitinib are some upcoming treatments. Budesonide foam will be used as one treatment option in patients with distal colitis. Herbal medicine is also effective for active UC. In the near future, physicians will able to use many different treatments for UC patients.


The rising incidence of ulcerative colitis disease across the globe is the major driving factor for the ulcerative colitis market. Furthermore, factors such as advancements in the healthcare industry in the past few years, the arrival of enhanced drugs, and increasing research explorations to develop an innovative treatment for ulcerative colitis are other driving factors for the growth of the market. Increasing demand for better treatment procedures along with developing healthcare infrastructures is fueling the ulcerative colitis market growth. However, stringent government regulations towards approval of biosimilars restrain the market growth. Moreover, unmet needs in the treatment of ulcerative colitis are expected to provide lucrative growth opportunities for the ulcerative colitis market.


Geographically, North America dominates the global ulcerative colitis market owing to the presence of key players and the growing prevalence of the disease in the region. The continuing funding for the development of new therapeutics for the treatment of the condition also drives the market growth in North America. Asia-Pacific is the second-largest market for ulcerative colitis due to expanding incidences of ulcerative colitis accompanied by the expansion of the drug development sector in this region. Ulcerative colitis is increasing in several parts of Asia with gender distribution and age of diagnosis.

Global Ulcerative Colitis Market


Segment Covered

The report on global ulcerative colitis market covers segments such as drug type and disease type. On the basis of drug type, the sub-markets include anti-inflammatory drugs, anti-TNF biologics, immunosuppressant, calcineurin inhibitors, and other drug types. On the basis of disease type, the sub-markets include ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis.


Companies Profiled:

The report provides profiles of the companies in the market such as GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Sanofi Aventis A/S, AstraZeneca plc, Abbott Laboratories, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., Avaxia Biologics Inc., and other companies.


Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of ulcerative colitis market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.

Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount